René Bernards

René Bernards is a professor of molecular carcinogenesis at the Netherlands Cancer Institute. His laboratory uses functional genomic approaches to find vulnerabilities of cancers that can be exploited therapeutically. His laboratory identified the combination of a BRAF inhibitor and an EGFR inhibitor as effective for the treatment of BRAF mutant colon cancer. He also developed the first clinically used gene expression test for early breast cancer prognosis: MammaPrint. Amongst his honors are the Pezcoller Foundation award, the Ernst Bertner Award for Cancer Research from the M.D. Anderson Cancer Center and the ESMO Lifetime Achievement Award. He is also a member of the Royal Netherlands Academy of Sciences and of the AACR Academy.

December 10, 2019 HUB Organoids in Financial Times December 10, 2019. Yesterday the Financial Times featured an article on Organoid Innovation: Organoid innovation offers ... read more
October 18, 2019 CrownBio launched patient-derived tumor organ... San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development pl... read more
October 01, 2019 Hubrecht Organoid Technology and MIMETAS to d... Leiden, Utrecht September 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategi... read more